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Background:Cilostazol and isosorbide mononitrate (ISMN) are candidate treatments for
cerebral small vessel disease and lacunar ischaemic stroke. As both drugs may influence
hemoglobin and platelet count, and hemodynamics, we sought to assess their effects in
the lacunar intervention-1 (LACI-1) trial.
Methods: Fifty-seven lacunar ischaemic stroke patients were randomized to immediate
ISMN, cilostazol, or their combination for 9 weeks in addition to guideline stroke
prevention. A fourth group received both drugs with a delayed start. Full blood count,
platelet function, peripheral blood pressure (BP), heart rate and central hemodynamics
(Augmentation index, Buckberg index) were measured at baseline, and weeks 3 and 8.
Differences were assessed by multiple linear regression adjusted for baseline and key
prognostic variables. Registration ISRCTN 12580546.
Results: At week 8, platelet count was higher with cilostazol vs. no cilostazol
(mean difference, MD 35.73, 95% confidence intervals, 95% CI 2.81–68.66, p =
0.033), but no significant differences were noted for hemoglobin levels or platelet
function. At week 8, BP did not differ between the treatment groups, whilst heart
rate was higher in those taking cilostazol vs. no cilostazol (MD 6.42, 95% CI
1.17–11.68, p = 0.017). Buckberg index (subendocardial perfusion) was lower in
those randomized to cilostazol vs. no cilostazol and in those randomized to both
drugs vs. either drug. Whilst ISMN significantly increased unadjusted augmentation
index (arterial stiffness, MD 21.19, 95% CI 9.08–33.31, p = 0.001), in isolation
both drugs non-significantly reduced augmentation index adjusted for heart rate.
Appleton et al. ISMN/Cilostazol in Lacunar Stroke
Conclusions: Cilostazol increased heart rate and platelet count, and reduced Buckberg
index, whilst both drugs may individually reduce arterial stiffness adjusted for heart rate.
Neither drug had clinically significant effects on hemoglobin or platelet function over 8
weeks. Further assessment of the safety and efficacy of these medications following
lacunar ischaemic stroke is warranted.
Keywords: cilostazol, isosorbide mononitrate, blood pressure, safety, platelets, lacunar stroke, randomized
clinical trial
INTRODUCTION
Cerebral small vessel disease (SVD) is a common cause of
stroke—both “lacunar” ischaemic and haemorrhagic stroke—
cognitive impairment and dementia (1). SVD is a disorder
of the small perforating arterioles of the brain involving
endothelial dysfunction, inflammation (2), and blood-brain
barrier breakdown (3). However, there are no specific treatments
for either primary or secondary prevention of SVD and its
associated clinical manifestations (4). Two medications with
potential beneficial mechanisms of action have been highlighted
for potential repurposing: cilostazol (a phosphodiesterase 3′
inhibitor used in stroke prevention in the Asia-Pacific Region)
and isosorbide mononitrate (ISMN, a nitric oxide donor widely
used in ischaemic heart disease). Little is known about the safety
and efficacy of these drugs in SVD, particularly in combination,
and yet their effects may be synergistic (4). As a mild antiplatelet,
cilostazol can cause bleeding sufficient to result in anemia.
Further, cilostazol can rarely cause thrombocythaemia (5). Both
drugs can lower peripheral blood pressure (BP) and increase
heart rate (5, 6), but data regarding their effects on central
hemodynamics following ischaemic lacunar stroke are lacking.
The Lacunar Intervention Trial-1 (LACI-1) tested cilostazol
and ISMN, alone and in combination, for tolerability in
patients with prior lacunar ischaemic stroke (7). Overall, the
medications were well-tolerated by participants (8). As both
drugs may influence platelet count and hemoglobin level in
addition to hemodynamics, we sought to assess these important
safety outcomes.
METHODS
Population
LACI-1 was a phase IIa, partial factorial, dose-escalation,
prospective, randomized, open-label, blinded endpoint (PROBE)
trial. Details regarding the trial protocol and statistical analysis
plan are available (7), and the main results have been presented
and published (8, 9). In summary, LACI-1 recruited 57
patients from stroke centers in Edinburgh and Nottingham,
UK, with clinically confirmed lacunar ischaemic stroke, without
dependency and able to consent themselves, and randomized
them to one of four groups for 9 weeks: ISMN 25mg twice
daily; cilostazol 100mg twice daily; both ISMN and cilostazol
Abbreviations: Bpm, beats per minute; BP, blood pressure; CI, confidence interval;
FBC, full blood count; ISMN, isosorbide mononitrate; MD, mean difference; SVD,
small vessel disease.
FIGURE 1 | P-selectin surface expression in response to arachidonic acid
(Aspirin test). AA, Arachidonic acid; ISMN, isosorbide mononitrate; MF, median
fluorescence.
started immediately; or both medications with a 3-week delayed
start, thus providing a drug-free control period (see Figure 1
in main paper) (8). Patients were contacted on alternate
weeks to enquire about symptoms (headache, nausea, diarrhea,
vomiting, and bleeding) using a structured questionnaire. All
patients continued to take guideline secondary stroke prevention
medications including statins and antihypertensive treatment
where appropriate. Hematology and haemodynamic measures
were assessed blind to treatment allocation.
All patients provided written informed consent. LACI-1
was approved by the Scotland A Research Ethics Committee
(15/SS/0154) and registered (ISRCTN 12580546).
Hematology and Platelet Function Testing
Full blood counts were taken at baseline, and at weeks 3 and 8:
hemoglobin (g/L); and platelet count (×109/L). Platelet function
was assessed with measurement of surface expression of P-
selectin (CD63P) using kits sensitive to aspirin (arachidonic acid)
or clopidogrel (adenosine diphosphate) at the same timepoints
(10). An unstimulated sample provided baseline expression data
at each timepoint. Median fluorescence (MF) was recorded for
platelet surface expression of P-selectin for each sample using
flow cytometry. Platelet P-selectin expression was chosen since
blood samples can be obtained and fixed at multiple clinical sites
then transported for measurement at a central core laboratory.
Haemodynamic Measures
Hemodynamics were measured at baseline and at weeks 3 and
8. Peripheral blood pressure (BP, mmHg) and heart rate (bpm)
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TABLE 1 | Baseline characteristics of LACI-1 participants.
All Both delayed ISMN Cilostazol Both immediate
Patients 57 15 15 13 14
Age (years)* 66.1 (11.1) 63.4 (11.5) 62.2 (11.0) 75.8 (8.7) 64.4 (8.1)
Sex, female 18 (31.6%) 6 (40.0%) 4 (26.7%) 5 (38.5%) 3 (21.4%)
Onset to randomization (days) 202.6 (256.2) 153.3 (180.4) 137.5 (214.2) 279.2 (324.7) 254.0 (290.7)
Systolic BP (mmHg) 147.3 (20.5) 141.8 (19.6) 150.9 (19.0) 146.1 (21.3) 150.4 (22.9)
Diastolic BP (mmHg) 83.3 (12.6) 82.9 (14.3) 86.6 (11.5) 79.3 (12.0) 83.7 (12.6)
Past medical history (%)
Treated hypertension 42 (73.7%) 11 (73.3%) 11 (73.3%) 12 (92.3%) 8 (57.1%)
Treated hyperlipidaemia 48 (84.2%) 11 (73.3%) 12 (80.0%) 13 (100.0%) 12 (85.7%)
Diabetes 11 (19.3%) 3 (20.0%) 3 (20.0%) 2 (15.4%) 3 (21.4%)
Atrial fibrillation 0 0 0 0 0
Myocardial infarction 1 (1.8%) 1 (6.7%) 0 0 0
Previous stroke 6 (10.5%) 1 (6.7%) 2 (13.3%) 1 (7.7%) 2 (14.3%)
Smoking 26 (45.6%) 10 (66.7%) 6 (40.0%) 6 (46.2%) 4 (28.6%)
Patient status
mRS, baseline [/6] 1.0 [0.0, 1.0] 1.0 [0.0, 2.0] 1.0 [1.0, 1.0] 1.0 [1.0, 1.0] 1.0 [0.0, 1.0]
Current NIHSS [/42] 0.0 [0.0, 1.0] 0.0 [0.0, 1.0] 0.0 [0.0, 1.0] 0.0 [0.0, 1.0] 0.5 [0.0, 1.0]
BP, blood pressure; ISMN, isosorbide mononitrate; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale.
*Significant difference between the treatment groups (p < 0.05), comparisons done and Kruskal-Wallis tests.
were measured three times sitting and three times standing at
each visit using a validated monitor. Central hemodynamics
were measured in duplicate using the SphygmoCor device at the
same timepoints: mean arterial pressure (MAP); Augmentation
index (%)—a measure of arterial stiffness; Buckberg index (%)—
a measure of subendocardial perfusion; and pulse wave velocity
(m/s)—ameasure of arterial stiffness, assessed using non-invasive
tonometry measurements taken at the radial and carotid arteries.
Sample Size and Statistics
The sample size calculation for LACI-1 was based on the ability
to detect a difference of 90 vs. 55% (i.e., an absolute difference
of 35%) between those reaching target dose on one drug vs.
both drugs. For 80% power, significance 0.05, a sample size of 55
was needed.
Data are number (%), mean (standard deviation, SD),
and median [interquartile quartiles, IQR]. Baseline differences
between treatment groups were assessed using chi-square
and Kruskal-Wallis tests. Differences in hemodynamics and
hematological measures were assessed by multiple linear
regression, adjusted for baseline values, age, SVD imaging
score and time to randomization. Haemodynamic measures
were also adjusted for baseline systolic BP. As heart rate
can lead to spurious results, Augmentation index (%) was
measured unadjusted and normalized to heart rate 75 bpm as is
standard practice. The resultant mean difference (MD) with 95%
confidence intervals (CI) are presented with significance set at p
< 0.05. Analyses were performed using SAS.
RESULTS
In total, 57 patients were recruited at mean 203 [median 256]
days after their index stroke with a mean age of 66 (11) years
and 18 (32%) were female (Table 1). Most participants (97%)
were on clopidogrel for stroke secondary prevention (guideline
therapy in the UK), the remainder on aspirin. Apart from the
cilostazol group being slightly older, baseline characteristics were
well-balanced across the treatment groups. One participant in the
delayed start group withdrew during follow-up.
Hematology and Platelet Function Testing
There were no differences in hemoglobin at week 8 between
treatment groups (Table 2). Platelet count was slightly higher in
those on cilostazol 286.8 × 109/L vs. no cilostazol 249.1 × 109/L
(MD 35.73, 95% CI 2.81 to 68.66, p = 0.033). No differences
were noted in platelet function between treatment groups in
aspirin or clopidogrel tests (Figures 1, 2). There was no difference
in bruising or bleeding with either medication in isolation or
combination during the study.
Hemodynamics
Full haemodynamic data were available for 56 participants.
Baseline peripheral BP and heart rate did not differ between
treatment groups (Table 1). At week 8, BP did not significantly
differ between the treatment groups, whilst heart rate was
significantly higher in those taking cilostazol 82.8 bpm vs. no
cilostazol 74.5 bpm (MD 6.42, 95% CI 1.17 to 11.68, p =
0.017, Table 3). Central MAP did not differ between treatment
groups at week 8. Buckberg index (subendocardial perfusion)
was reduced in those randomized to cilostazol 142.2% vs. no
cilostazol 160.7% (MD −10.81, 95% CI −21.15 to −0.47, p =
0.040) and in those randomized to both drugs 148.9% vs. either
drug 159.9% (MD −11.37, 95% CI −21.01 to −1.72, p = 0.021).
Unadjusted Augmentation index was significantly higher (i.e.,
increased arterial stiffness) in those randomized to ISMN 123.8%
vs. no ISMN 119.8% (MD 21.19, 95% CI 9.08 to 33.31, p= 0.001).
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FIGURE 2 | P-selectin surface expression in response to adenosine
diphosphate (Clopidogrel test). ADP, adenosine diphosphate; ISMN,
isosorbide mononitrate; MF, median fluorescence.
In contrast, when adjusted for heart rate there was a tendency
toward lower Augmentation index (i.e., less arterial stiffness) in
those randomized to cilostazol 18.7% vs. no cilostazol 20.6% (MD
−4.79, 95% CI −9.72 to 0.15, p = 0.057) and ISMN 16.1% vs. no
ISMN 23.5% (MD −4.74, 95% CI −9.78 to 0.30, p = 0.066). No
differences in pulse wave velocity were seen.
DISCUSSION
In this secondary analysis of the LACI-1 trial—the first trial
to assess cilostazol and/or ISMN in lacunar ischaemic stroke
patients, and the first trial to assess both together in any ischaemic
stroke—we have demonstrated that cilostazol and ISMN in
isolation and in combination do not influence hemoglobin levels
or platelet function in the short-term when given in addition to
usual secondary stroke prevention therapy. Platelet count was
significantly higher in those randomized to cilostazol. Cilostazol
alone and both drugs in combination, reduced Buckberg index
(subendocardial perfusion), whilst cilostazol increased heart rate.
Both drugs in isolation may reduce arterial stiffness when
adjusted for heart rate.
Due to its mild antiplatelet effects, cilostazol can uncommonly
(≥1/100 to <1/10) cause bleeding sufficient to lead to anemia
according to the summary of product characteristics (SmPC)
(5). Although we have a small population, it is reassuring
that hemoglobin was stable between treatment groups during
the trial given that all participants were already on guideline
antiplatelet therapy. The increase in platelet count seen with
cilostazol at 8 weeks needs further investigation, especially since
thrombocythaemia, is known to occur rarely (≥1/10,000 to
<1/1,000) (5). The lack of any difference in platelet function
between the treatment groups is of further reassurance.
ISMN is known to lower BP and increase heart rate
and so can commonly lead to postural dizziness (≥1/100 to
<1/10) and rarely syncope (6). Cilostazol can increase heart
rate and, if co-administered with BP-lowering medication, an
additive hypotensive effect with reflex tachycardia is reported
(5). Neither symptom were apparent across the trial population
(8). Importantly, despite cilostazol increasing heart rate in
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our population, no significant hypotensive effect was seen in
combination with participants’ pre-prescribed antihypertensives
(74% were on antihypertensives at randomization) or ISMN.
Central haemodynamic data regarding cilostazol and/or ISMN
in the context of lacunar ischaemic stroke are lacking. Buckberg
index is a marker of subendocardial perfusion, which is
reduced with increased heart rate (11). Cilostazol and both
drugs in combination reduced Buckberg index, which may
be due to their underlying effects on heart rate, or may
reflect that the patients allocated to cilostazol were older than
those in other allocated groups. ISMN was associated with
increased Augmentation index (a marker of arterial stiffness)
unadjusted for heart rate, but when Augmentation index was
adjusted for heart rate, cilostazol and ISMN in isolation both
non-significantly reduced arterial stiffness. Given that small
vessel stiffness is implicated in the pathophysiology of cerebral
SVD (12), medications that reduce arterial stiffness may be
of benefit.
The strengths of this LACI-1 substudy include using data
from the first randomized controlled trial assessing both
cilostazol and ISMN in lacunar ischaemic stroke patients. There
are, however, limitations. First, the sample size was small
and the study was not powered to look for differences in
hematological or haemodynamic secondary outcomes, therefore
some findings may represent chance. Second, the treatment
duration was relatively short and so we cannot comment on
the longer-term effects of these medications on hematological
markers or hemodynamics. Third, those who were randomized
to cilostazol were older which may explain some of the
reported differences in these outcomes. Last, there was
no formal control group throughout the trial, rather the
delayed start group represented a drug-free control period.
This gave the opportunity to establish whether starting one
drug first over the other impacted upon side-effects, whilst
still providing a control group for the first 3 weeks of
the study.
In summary, cilostazol and ISMN were safe in isolation
and combination in the short- to medium-term in this
small population following lacunar ischaemic stroke.
Further data from larger trials are required to establish
the longer term effects of these medications on safety and
efficacy following lacunar ischaemic stroke. As such, the
LACI-2 study is testing their effects on stroke recurrence,
cognitive function, imaging features of SVD and safety when
given for 12 months in patients with lacunar ischaemic
stroke (ISRCTN14911850).
DATA AVAILABILITY
The datasets generated for this study are available on request to
the corresponding author.
ETHICS STATEMENT
LACI-1 was approved by the Scotland A Research Ethics
Committee (15/SS/0154) and registered (ISRCTN 12580546).
Frontiers in Neurology | www.frontiersin.org 5 July 2019 | Volume 10 | Article 723
Appleton et al. ISMN/Cilostazol in Lacunar Stroke
AUTHOR CONTRIBUTIONS
JA: recruitment, data collection, analysis, and manuscript
preparation. GB and ZL: recruitment, data collection, analysis,
and manuscript editing. KF and LW: statistical analysis,
manuscript preparation, and editing. JM: platelet function
testing. FD and NS: study design, supervision, study set up,
data collection, SAE adjudication, and manuscript editing.
PB: trial conception, design, management, supervision, data
collection and analysis, and manuscript editing. JW: trial
conception, design, funding, supervision, data collection,
analysis, manuscript editing, and overall guarantor.
FUNDING
LACI-1 is funded by the Alzheimer’s Society Ref: 252 (AS-
PG-14-033). Additional support is provided by the European
Union Horizon 2020 project No 666881, SVDs@Target (GB),
the Stroke Association Princess Margaret Research Development
Fellowship scheme (GB), the Stroke Association GarfieldWeston
Foundation Stroke Association Senior Clinical Lectureship
(FD), NHS Research Scotland (FD), NHS Lothian Research
and Development Office and the Scottish Funding Council
through the Scottish Imaging Network, A Platform for Scientific
Excellence (SINAPSE) Collaboration. Funding is gratefully
acknowledged from the Foundation Leducq (ref no. 16 CVD 05)
and Edinburgh and Lothians Health Foundation. JA and LW are
supported, in part, by the National Institutes of Health Research
(NIHR) HTA TARDIS and BHF RIGHT-2 trials. ZL and KF are
supported, in part, by the NIHR HTA TICH-2 trial. PB is Stroke
Association Professor of Stroke Medicine, and is a NIHR Senior
Investigator. LACI-1 was adopted by the NIHR CRN.
ACKNOWLEDGMENTS
Data contributing to this manuscript were presented, in part, as
posters at the European Stroke Organization Conference (ESOC)
in Gothenburg, Sweden May 2018: Appleton et al. (13, 14).
REFERENCES
1. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms
and clinical implications. Lancet Neurol. (2019) 18: 684–96.
doi: 10.1016/S1474-4422(19)30079-1
2. Wiseman S, Marlborough F, Doubal F, Webb DJ, Wardlaw J. Blood markers
of coagulation, fibrinolysis, endothelial dysfunction and inflammation in
lacunar stroke versus non-lacunar stroke and non-stroke: systematic review
and meta-analysis. Cerebrovasc Dis. (2014) 37:64–75. doi: 10.1159/000356789
3. Wardlaw JM, Makin SJ, Valdés Hernández MC, Armitage PA, Heye AK,
Chappell FM, et al. Blood-brain barrier failure as a coremechanism in cerebral
small vessel disease and dementia: evidence from a cohort study. Alzheimer
Dement. (2017) 13:634–43. doi: 10.1016/j.jalz.2016.09.006
4. Bath P, Wardlaw J. Pharmacological treatment and prevention of cerebral
small vessel disease: a review of potential interventions. Stroke. (2015) 10:469–
78. doi: 10.1111/ijs.12466
5. EuropeanMedicines Agency.Cilostazol—Summary of Product Characteristics.
(2016). Available online at: https://www.medicines.org.uk/emc/product/3379/
smpc (accessed September 1, 2018).
6. SmPC. Isosorbide Mononitrate—Summary of Product Characteristics. (2014).
Available online at: https://www.medicines.org.uk/emc/product/6115/smpc
(accessed September 1, 2018).
7. Blair GW, Appleton JP, Law ZK, Doubal F, Flaherty K, Dooley R, et al.
Preventing cognitive decline and dementia from cerebral small vessel disease:
the LACI-1 trial. protocol and statistical analysis plan of a phase IIa dose
escalation trial testing tolerability, safety and effect on intermediary endpoints
of isosorbide mononitrate and cilostazol, separately and in combination. Int J
Stroke. (2018) 13:530–8. doi: 10.1177/1747493017731947
8. Blair GW, Appleton JP, Flaherty K, Doubal F, Sprigg N, Dooley R,
et al. Tolerability, safety and intermediary pharmacological effects
of cilostazol and isosorbide mononitrate, alone and combined, in
patients with lacunar ischaemic stroke: the LACunar Intervention-1
(LACI-1) trial, a randomised clinical trial. EClinicalMedicine. (in press).
doi: 10.1016/j.eclinm.2019.04.001
9. Blair GW, Appleton JP, Flaherty K, Sprigg N, Doubal F, Boyd J, et al.
Preventing cognitive decline and dementia from cerebral small vessel disease:
the LACI-1 trial. Int J Stroke. (2017) 12 (5 Suppl. 2):15.
10. Bath PM, May J, Flaherty K, Woodhouse LJ, Dovlatova
N, Fox SC, et al. Remote assessment of platelet function
in patients with acute stroke or transient ischaemic attack.
Stroke Res Treat. (2017) 2017:7365684. doi: 10.1155/2017/73
65684
11. Buckberg GD, Fixler DE, Archie JP, Hoffman JI. Experimental subendocardial
ischemia in dogs with normal coronary arteries. Circ Res. (1972) 30:67–81.
doi: 10.1161/01.RES.30.1.67
12. Del Bene A, Makin SD, Doubal FN, Wardlaw JM. Do risk factors for
lacunar ischaemic stroke vary with the location or appearance of the lacunar
infarct? Cerebrovasc Dis. (2012) 33:21.
13. Appleton JP, Flaherty K, Blair GW, Law ZK, Doubal F, Sprigg N, et al.
Platelet and haemoglobin levels in patients on isosorbide mononitrate and/or
cilostazol with lacunar ischaemic stroke: data from the LACI-1 trial. Eur Stroke
J. (2018) 3:488–9.
14. Appleton JP, Blair GW, Flaherty K, Law ZK, Doubal F, Sprigg N, et al.
Peripheral and central haemodynamics in patients on isosorbide mononitrate
and/or cilostazol with lacunar ischaemic stroke: data from the LACI-1 trial.
Eur Stroke J. (2018) 3:489.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Appleton, Blair, Flaherty, Law, May, Woodhouse, Doubal, Sprigg,
Bath and Wardlaw. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 6 July 2019 | Volume 10 | Article 723
